Biopsy Devices

Global Biopsy Devices Market to Reach US$5.9 Billion by 2030

The global market for Biopsy Devices estimated at US$4.5 Billion in the year 2024, is expected to reach US$5.9 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Ultrasound-Guided Biopsy Devices, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$2.4 Billion by the end of the analysis period. Growth in the CT Scan-Guided Biopsy Devices segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 4.2% CAGR

The Biopsy Devices market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$924.7 Million by the year 2030 trailing a CAGR of 4.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.5% and 3.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Biopsy Devices Market - Key Trends and Drivers Summarized

Why Are Biopsy Devices Gaining Attention?

Biopsy devices have become a cornerstone in the diagnostic process, particularly in the early detection and monitoring of various cancers. Recent technological advancements in biopsy devices have significantly improved their accuracy, safety, and patient comfort. From traditional needle biopsies to advanced image-guided and robotic-assisted techniques, the evolution of these devices is remarkable. These innovations have not only enhanced the precision of tissue sampling but also minimized the invasiveness of the procedure, leading to quicker recovery times and fewer complications. The integration of imaging technologies like ultrasound, MRI, and CT scans with biopsy devices has further revolutionized the field, enabling real-time guidance during the procedure and ensuring that the samples collected are from the most relevant areas, thereby increasing diagnostic accuracy.

How Are End-Use Trends Shaping the Biopsy Devices Market?

The utilization of biopsy devices is seeing a notable shift, driven by changes in end-use trends within the healthcare sector. With the rising incidence of cancer and other chronic diseases, there is an increasing demand for early and accurate diagnostic tools. Hospitals and diagnostic centers are the primary users of biopsy devices, but there’s a growing trend of outpatient clinics and specialized cancer centers adopting these technologies. This shift is largely due to the emphasis on early detection and personalized medicine, which requires precise and timely diagnosis. Moreover, the aging global population, coupled with the growing awareness of regular health check-ups, is driving the demand for routine biopsy procedures. This trend is particularly noticeable in developed regions, where healthcare infrastructure supports advanced diagnostic practices, but emerging markets are quickly catching up, further fueling the demand for these devices.

What Innovations Are Shaping the Future of Biopsy Devices?

The future of biopsy devices is being shaped by continuous innovations aimed at improving patient outcomes and diagnostic accuracy. One of the most significant developments is the advent of liquid biopsies, which offer a less invasive alternative to traditional tissue biopsies. Liquid biopsies analyze circulating tumor cells or DNA from a blood sample, providing crucial information about the presence and progression of cancer without the need for surgery. Another area of innovation is the development of single-use, disposable biopsy devices that reduce the risk of cross-contamination and infection. These devices are particularly valuable in settings where sterility is a top priority. Additionally, advancements in robotic-assisted biopsy procedures are enhancing the precision and consistency of sample collection, reducing human error, and enabling more complex procedures to be performed with greater ease. These innovations are not only improving the efficiency of the biopsy process but are also expanding the range of conditions that can be diagnosed through biopsy.

What’s Driving the Growth in the Biopsy Devices Market?

The growth in the biopsy devices market is driven by several factors. The rising prevalence of cancer and other chronic diseases has led to an urgent need for early and accurate diagnosis, which is one of the primary drivers of market growth. Technological advancements, such as the integration of imaging technologies and the development of less invasive biopsy techniques, have significantly improved the accuracy and safety of biopsies, making them more accessible and acceptable to patients. Additionally, the trend toward personalized medicine is fueling demand for precise diagnostic tools, as treatments are increasingly tailored to the specific characteristics of an individual’s disease. Moreover, the expansion of healthcare infrastructure in emerging markets is creating new opportunities for the adoption of advanced biopsy devices. Government initiatives and funding for cancer research and early diagnosis programs are also playing a crucial role in supporting market growth. As awareness of the importance of early detection continues to grow, the biopsy devices market is expected to experience sustained demand, driven by both technological innovations and shifts in healthcare practices globally.

SCOPE OF STUDY:

The report analyzes the Biopsy Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Imaging Technology (Ultrasound-Guided Biopsy, CT Scan-Guided Biopsy, MRI-Guided Biopsy, Steretactics-Guided Biopsy, Other Imaging Technologies); End-Use (Hospitals, Diagnostics Centers)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 46 Featured) -

• Argon Medical Devices, Inc.
• B. Braun Melsungen AG
• BARD, A Becton, Dickinson Company
• Becton, Dickinson and Company
• Boston Scientific Corporation
• Cardinal Health, Inc.
• Cook Group, Inc.
• FUJIFILM Holdings Corporation
• Hologic, Inc.
• Inrad, Inc.
• Medtronic PLC
• Olympus Corporation

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.